Medical Marijuana Inc (MJNA)

[Ecostate]

MJNA/Kannalife is a biopharmaceutical company focused on discovering, developing and commercializing a product platform of novel molecules from our proprietary next generation cannabinoid therapeutics as potent, non-opioid alternatives to treat patients with a variety of unmet medical needs. Since 2010, we have been principally involved in the research and development of synthetic cannabidiol (“CBD”) therapeutics through pre-clinical drug discovery and development processes. We have developed our own intellectual property portfolio and established relationships with globally recognized third parties who are considered leaders in active pharmaceutical (“API”) contract manufacturers, formulators and contract bulk drug manufacturers. From 2012 to 2019, Kannalife held an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife has also developed its own patented molecules lead by KLS-13019 called by Sports Illustrated as a “super-CBD” and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy” and U.S. Patent #10004722, “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols.” https://www.kannalife.com/about/
https://www.kannalife.com/category/news/